UK: +44 1379 658 721
Ireland: +353 89 221 3723
USA: +1 754 252 3536
Middle East - N. Africa: + 971 52 873 4738
Australia: +61 3 9310 5259
Kate Bingham used to be the head of the UK’s Vaccine Taskforce. She’s just slammed the UK government in a New Scientist article, claiming the government has ‘missed chances to maximise vaccine manufacturing capacity’ and has ‘no strategic plan for research that could help prevent another pandemic’.
Bingham is shocked by several of the government’s decisions. For a start they’ve stopped steering vaccine research and development to prioritise new technologies that could be strategically vital. The government has also missed opportunities to maximise UK manufacturing capacity. And while we do have more capacity than we used to, the facilities remain ‘inadequate’.
What qualifies her to be so critical? May 2020 saw Kate an unpaid, seven-month break from her job as a biotech venture capitalist to oversee the speedy development and purchase of millions of covid vaccine doses. If there’s anyone to thank to the nation’s initial fast vaccine response, it’s her.
By December 2020 the brilliant Pfizer/BioNTech vaccine was being widely used and shortly after that the Oxford/AstraZeneca vaccine arrived, rolled out to the vulnerable quickly and efficiently thanks to huge teams of volunteers and the NHS.
At the same time the task force Kate was overseeing was supposed to build permanent ‘pandemic resilience’, but it didn’t happen. While the UK still funds basic medical research that might deliver better covid vaccines - and vaccines against the next pandemic we will face - there’s ‘little central oversight or strategic planning’. While we do have more vaccine manufacturing opportunities here, it ‘can be hard for academics to get funding through the usual mechanisms of government grants’. In Kate’s words there’s ‘no coordination’.
There’s more. The UK government has also changed its mind about a deal it made to buy 100 million doses of covid vaccine from the French firm Valneva, which seems very odd when ‘positive final-stage clinical trial results were announced’ only a month later. The change of plan not only affected future jobs at the firm’s Scottish plant but also means we won’t, after all, benefit from diversified vaccine capabilities, leaving the UK less able to help low-income countries out with donated vaccines. And if we fail to help other countries beat covid, more variants and subvariants will have the chance to develop.
The sale of the UK’s Vaccine Manufacturing and Innovation Centre, which helped develop the Oxford/AstraZeneca jab, has also baffled experts. More worryingly, the government won’t say why it made the decision, and refused to talk to New Scientist journalists about the matter. Last but not least Kate Bingham’s worries extend to the government’s puzzling U-turn on plans to make the nation more appealing for clinical trials in future. What they’ve actually done is miss a one-time opportunity that won’t come again.
In the face of these let-downs, can business owners step into the howling gap and do something to help? Yes, you can. Our affordable UVC sterilisers make short, fast work of killing covid, stopping the spread. Fit them at your place and you’ll do your bit to keep the UK economy running. Get in touch if you’d like to know more or talk about the potential for UVC covid disinfection at your place.